JCP
CLDX icon

Jabre Capital Partners’s Celldex Therapeutics CLDX Stock Holding History

Jabre Capital Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-10,000
Closed -$2.45M – 125
2014
Q2 		$2.45M Buy
10,000
+2,000
+25% +$452K 0.17% 105
2014
Q1 		$2.12M Buy
+8,000
New +$3.06M 0.2% 92

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Jabre Capital Partners's CLDX Position: Q3 2014 in Review

Jabre Capital Partners sold out of Celldex Therapeutics (CLDX) in Q3 2014, closing a stake of 10,000 shares — an estimated $2.45M sold.

Jabre Capital Partners first reported a position in CLDX in Q1 2014 and held it in 2 quarters. The position peaked at $2.45M in Q2 2014. 148 funds tracked by Wall St. Rank hold CLDX as of Q3 2014.

  • Jabre Capital Partners reported no remaining Celldex Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Jabre Capital Partners sold 10,000 Celldex Therapeutics shares in Q3 2014, an estimated $2.45M.
  • Jabre Capital Partners first reported a position in Celldex Therapeutics in Q1 2014 and held it in 2 quarters.
  • Jabre Capital Partners's Celldex Therapeutics position peaked at $2.45M in Q2 2014.
  • 148 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2014.

Based on Jabre Capital Partners's 13F filing for Q3 2014, filed 14 Nov 2014.